Tandutinib (CT53518, MLN518, CT-53518, MLN-518) (CAS: 387867-13-2) is a small molecule inhibitor of receptor tyrosine kinases (RTKs), which are proteins involved in intracellular signaling pathways. It has been investigated as a potential anticancer agent, particularly for the treatment of leukemia and other hematological malignancies.
Chemical name: N-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(4-methylpiperazin-1-yl)benzo[b]thiophene-2-carboxamide
Molecular formula: C28H27N7O2S
Formula weight: 529.63 g/mol
CAS No: 387867-13-2
Top ten keywords from Google:
Synonyms:
Health benefits of this product: Tandutinib has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of leukemia and other hematological malignancies. Its primary mode of action is through the inhibition of RTKs, leading to reduced cell proliferation and increased apoptosis.
Potential effects: Tandutinib has demonstrated efficacy in several preclinical studies in inhibiting the activity of RTKs, particularly in cells with FLT3 mutations that are commonly associated with leukemia. It also has potential benefits for inducing apoptosis (programmed cell death) of cancer cells and inhibiting angiogenesis, which is the formation of new blood vessels that can support tumor growth. Tandutinib works by disrupting signal transduction pathways in cancer cells, leading to reduced proliferation and survival.
Product mechanism: Tandutinib works by inhibiting the activity of RTKs, which are proteins involved in intracellular signaling pathways that regulate cell proliferation, differentiation, and survival. In particular, it targets FLT3, a type of RTK that is commonly mutated in patients with leukemia. By inhibiting FLT3 activity, tandutinib can disrupt signal transduction pathways in cancer cells and induce programmed cell death (apoptosis).
Safety: Tandutinib has been evaluated in several clinical trials involving hundreds of participants and has been generally well-tolerated. Rare but potential side effects may include nausea, vomiting, diarrhea, headache, and allergic reactions. Patients with liver or kidney disease should exercise caution when taking tandutinib, as it may affect these conditions. Pregnant or breastfeeding women should avoid using tandutinib, as its safety in these populations has not been established.
Side effects: Common side effects of tandutinib may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of tandutinib may vary depending on the patient's condition and treatment goals. In clinical trials, doses ranging from 50 to 650 mg per day have been evaluated for leukemia and other hematological malignancies. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Tandutinib (CT53518, MLN518, CT-53518, MLN-518) (CAS: 387867-13-2) is a small molecule inhibitor of RTKs that has been investigated as a potential anticancer agent, particularly for the treatment of leukemia and other hematological malignancies. Its primary mode of action is through the inhibition of FLT3, leading to reduced cell proliferation and increased apoptosis. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and its long-term safety profile.
